Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$2.41
-1.5%
$4.44
$2.09
▼
$7.65
$137.96M1.51.37 million shs4.47 million shs
Alkermes plc stock logo
ALKS
Alkermes
$44.94
-2.7%
$43.71
$27.00
▼
$55.67
$7.55B0.322.09 million shs743,430 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$609.38
-3.9%
$634.13
$373.00
▼
$693.97
$17.05B1.12321,863 shs187,284 shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$32.49
-2.1%
$35.12
$31.75
▼
$55.00
$1.49B0.88636,533 shs433,166 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-10.26%+6.99%-46.74%-59.77%-41.67%
Alkermes plc stock logo
ALKS
Alkermes
-1.43%-1.70%+4.69%-4.45%+60.96%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-1.99%-3.48%+1.86%+2.13%+7.06%
Omnicell, Inc. stock logo
OMCL
Omnicell
-4.27%-5.06%-9.07%-6.75%-3.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$2.41
-1.5%
$4.44
$2.09
▼
$7.65
$137.96M1.51.37 million shs4.47 million shs
Alkermes plc stock logo
ALKS
Alkermes
$44.94
-2.7%
$43.71
$27.00
▼
$55.67
$7.55B0.322.09 million shs743,430 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$609.38
-3.9%
$634.13
$373.00
▼
$693.97
$17.05B1.12321,863 shs187,284 shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$32.49
-2.1%
$35.12
$31.75
▼
$55.00
$1.49B0.88636,533 shs433,166 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-10.26%+6.99%-46.74%-59.77%-41.67%
Alkermes plc stock logo
ALKS
Alkermes
-1.43%-1.70%+4.69%-4.45%+60.96%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-1.99%-3.48%+1.86%+2.13%+7.06%
Omnicell, Inc. stock logo
OMCL
Omnicell
-4.27%-5.06%-9.07%-6.75%-3.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
2.67
Moderate Buy$21.00769.93% Upside
Alkermes plc stock logo
ALKS
Alkermes
2.65
Moderate Buy$55.7324.03% Upside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.23
Hold$649.276.55% Upside
Omnicell, Inc. stock logo
OMCL
Omnicell
2.90
Moderate Buy$57.8678.09% Upside

Current Analyst Ratings Breakdown

Latest ALKS, ABEO, MEDP, and OMCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Alkermes plc stock logo
ALKS
Alkermes
DowngradeHold (C) ➝ Hold (C-)
11/13/2026
Omnicell, Inc. stock logo
OMCL
Omnicell
Reiterated RatingNeutral
11/10/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
DowngradeSell (D) ➝ Sell (D-)
11/9/2026
Omnicell, Inc. stock logo
OMCL
Omnicell
DowngradeHold (C) ➝ Hold (C-)
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Reiterated RatingHold (C)
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetOverweight$65.00 ➝ $68.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Set Price Target$61.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetOutperform$56.00 ➝ $57.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetNeutral$43.00 ➝ $50.00
11/4/2026
Omnicell, Inc. stock logo
OMCL
Omnicell
UpgradeHold ➝ Strong-Buy
10/26/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Boost Price TargetMarket Perform$600.00 ➝ $670.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.82M23.70N/AN/A$2.20 per share1.10
Alkermes plc stock logo
ALKS
Alkermes
$1.48B5.12$1.61 per share27.98$11.10 per share4.05
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.84B6.01$16.03 per share38.02$20.91 per share29.14
Omnicell, Inc. stock logo
OMCL
Omnicell
$1.18B1.26$2.59 per share12.53$28.64 per share1.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$71.18M-$1.07N/AN/AN/A-160.30%-44.82%-32.51%N/A
Alkermes plc stock logo
ALKS
Alkermes
$241.66M-$0.02N/A124.82N/A-0.02%0.40%0.19%N/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$451.12M$18.0433.7831.202.5118.24%99.76%24.47%2/8/2027 (Estimated)
Omnicell, Inc. stock logo
OMCL
Omnicell
$2.05M$0.9633.8427.770.803.59%5.69%3.61%2/4/2027 (Estimated)

Latest ALKS, ABEO, MEDP, and OMCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.1743-$0.08+$0.0943-$0.08$14.82 million$13.49 million
11/4/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0818$0.09+$0.1718$0.09$463.48 million$480.13 million
10/29/2026Q3 2026
Omnicell, Inc. stock logo
OMCL
Omnicell
$0.4175$0.58+$0.1625$0.24$304.44 million$307.85 million
10/21/2026Q3 2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$4.44$4.84+$0.40$4.84$714.47 million$716.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/A
5.69
5.52
Alkermes plc stock logo
ALKS
Alkermes
0.79
2.42
2.02
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.83
0.83
Omnicell, Inc. stock logo
OMCL
Omnicell
0.13
1.65
1.45

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%
Omnicell, Inc. stock logo
OMCL
Omnicell
97.70%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
7.10%
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.50%
Omnicell, Inc. stock logo
OMCL
Omnicell
2.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
22657.15 million53.09 millionOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050168.04 million160.33 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
6,20027.97 million22.24 millionOptionable
Omnicell, Inc. stock logo
OMCL
Omnicell
3,58045.99 million44.65 millionOptionable

Recent News About These Companies

Here's Why Omnicell (OMCL) is a Strong Value Stock
FY2026 EPS Forecast for Omnicell Increased by Analyst
Best Momentum Stocks to Buy for November 5th
New Strong Buy Stocks for November 5th
Best Value Stocks to Buy for November 5th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$2.41 -0.04 (-1.47%)
Closing price 03:59 PM Eastern
Extended Trading
$2.45 +0.04 (+1.49%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Alkermes stock logo

Alkermes NASDAQ:ALKS

$44.94 -1.25 (-2.70%)
Closing price 03:59 PM Eastern
Extended Trading
$44.95 +0.02 (+0.03%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Medpace stock logo

Medpace NASDAQ:MEDP

$609.38 -24.60 (-3.88%)
Closing price 03:59 PM Eastern
Extended Trading
$610.33 +0.95 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Omnicell stock logo

Omnicell NASDAQ:OMCL

$32.49 -0.69 (-2.09%)
Closing price 03:59 PM Eastern
Extended Trading
$32.52 +0.03 (+0.10%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.